Search

Your search keyword '"Viganò, Maria Grazia"' showing total 26 results
Start Over Author "Viganò, Maria Grazia"
26 results on '"Viganò, Maria Grazia"'

1. Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle?

Author

Venanzi, Francesco Maria, Bini, Marta, Nuccio, Antonio, De Toma, Alessandro, Lambertini, Matteo, Ogliari, Francesca Rita, Oresti, Sara, Viganò, Maria Grazia, Brioschi, Elena, Polignano, Maggie, Naldini, Matteo Maria, Riva, Silvia, Ferrara, Michele, Fogale, Nicola, Damiano, Giuseppe, Russo, Vincenzo, Reni, Michele, Veronesi, Giulia, Foggetti, Giorgia, Conforti, Fabio, Bulotta, Alessandra, and Ferrara, Roberto

Published
2023
Full Text
View/download PDF

3. Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study

Author

Morabito, Alessandro, Gebbia, Vittorio, Di Maio, Massimo, Cinieri, Saverio, Viganò, Maria Grazia, Bianco, Roberto, Barbera, Santi, Cavanna, Luigi, De Marinis, Filippo, Montesarchio, Vincenzo, Costanzo, Raffaele, Sandomenico, Claudia, Montanino, Agnese, Mancuso, Gianfranco, Russo, Paolo, Nacci, Angelo, Giordano, Pasqualina, Daniele, Gennaro, Piccirillo, Maria Carmela, Rocco, Gaetano, Gridelli, Cesare, Gallo, Ciro, and Perrone, Francesco

Published
2013
Full Text
View/download PDF

5. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials

Author

Gridelli, Cesare, Morabito, Alessandro, Gebbia, Vittorio, Mencoboni, Manlio, Carrozza, Francesco, Viganò, Maria Grazia, Verusio, Claudio, Bollina, Roberto, Mattioli, Rodolfo, Valerio, Maria Rosaria, Valmadre, Giuseppe, Maione, Paolo, Rossi, Antonio, Cascone, Tina, Morgillo, Floriana, Di Maio, Massimo, Piccirillo, Maria Carmela, Gallo, Ciro, Perrone, Francesco, and Ciardiello, Fortunato

Published
2010
Full Text
View/download PDF

6. Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer

Author

Gregorc, Vanesa, primary, Lazzari, Chiara, additional, Mandalá, Mario, additional, Ippati, Stefania, additional, Bulotta, Alessandra, additional, Cangi, Maria Giulia, additional, Khater, Abdelrahman, additional, Viganò, Maria Grazia, additional, Mirabile, Aurora, additional, Pecciarini, Lorenza, additional, Ogliari, Francesca Rita, additional, Arrigoni, Gianluigi, additional, Grassini, Greta, additional, Veronesi, Giulia, additional, and Doglioni, Claudio, additional

Published
2021
Full Text
View/download PDF

16. Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

Author

Giovannini, Monica, Gregorc, Vanesa, Belli, Carmen, Roca, Elisa, Lazzari, Chiara, Viganò, Maria Grazia, Serafico, Anna, and Villa, Eugenio

Subjects
Article Subject
Abstract

Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typical pattern of cutaneous reactions. In this paper we reviewed the current available data regarding the clinical significance of skin reaction due to EGFR targeted agents. We show that skin toxicity can be considered as predictive marker of response to such drugs and that it is not disease specific; however its potential prognostic value is still to be proven.

Published
2009
Full Text
View/download PDF

17. Impact of treatment-free interval (TFI) and disease control rate (DCR) on survival outcome in relapsed malignant pleural mesothelioma (MPM).

Author

Gregorc, Vanesa, primary, Bulotta, Alessandra, additional, Viganò, Maria Grazia, additional, Ghio, Domenico, additional, Rossoni, Gilda, additional, Sallemi, Claudio, additional, Fontana, Floriana, additional, Ammannati, Cristina, additional, Colombi, Scialini, additional, Lambiase, Antonio, additional, and Bordignon, Claudio, additional

Published
2014
Full Text
View/download PDF

20. Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study.

Author

Morabito, Alessandro, primary, Gebbia, Vittorio, additional, Cinieri, Saverio, additional, Viganò, Maria Grazia, additional, Bianco, Roberto, additional, Barbera, Santi, additional, Cavanna, Luigi, additional, De Marinis, Filippo, additional, Montesarchio, Vincenzo, additional, Costanzo, Raffaele, additional, Sandomenico, Claudia, additional, Montanino, Agnese, additional, Mancuso, Gianfranco, additional, Nacci, Angelo, additional, Giordano, Pasqualina, additional, Daniele, Gennaro, additional, Gridelli, Cesare, additional, Rocco, Gaetano, additional, Gallo, Ciro, additional, and Di Maio, Massimo, additional

Published
2013
Full Text
View/download PDF

26. PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.

Author

Mirabile, Aurora, Brioschi, Elena, Ducceschi, Monika, Piva, Sheila, Lazzari, Chiara, Bulotta, Alessandra, Viganò, Maria Grazia, Petrella, Giovanna, Gianni, Luca, and Gregorc, Vanesa

Subjects
ANTIGENS, AUTOIMMUNE disease diagnosis, BRAIN diseases, AUTOIMMUNE diseases, DRUG toxicity, FACIAL paralysis, IMMUNOTHERAPY, LUNG cancer, MONOCLONAL antibodies, MYASTHENIA gravis, NEUROTOXICOLOGY, PHYSICIANS, POLYNEUROPATHIES, SYNDROMES, TUMOR classification, SYSTEMATIC reviews, HEALTH literacy, THERAPEUTICS
Abstract

The advent of immune checkpoint inhibitors gave rise to a new era in oncology and general medicine. The increasing use of programmed death-1 (PD-1) inhibitors in non-small cell lung cancer and in other malignancies means clinicians have to face up to new challenges in managing immune-related adverse events (irAEs), which often resemble autoimmune diseases. Neurological irAEs represent an emerging toxicity related to immunotherapy, and it is mandatory to know how to monitor, recognize, and manage them, since they can rapidly lead to patient death if untreated. Guidelines for the diagnosis and treatment of these irAEs have been recently published but sharing some of the most unusual clinical cases is crucial, in our opinion, to improve awareness and to optimize the approach for these patients. A literature review on the diagnosis and treatment of immune-related neurotoxicity's has been conducted starting from the report of four cases of neurological irAEs regarding cases of polyneuropathy, myasthenia gravis, Bell's palsy, and encephalopathy, all of which occurred in oncological patients receiving PD-1 inhibitors (pembrolizumab and nivolumab) for the treatment of non-oncogene addicted advanced non-small cell lung cancer. The exclusion of other differential diagnoses and the correlation between the suspension of immunotherapy and improvement of symptoms suggest that immunotherapy could be the cause of the neurological disorders reported. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results